Aldeyra Therapeutics To Announce Top-Line Results From The Phase 3 INVIGORATE‑2 Trial In Allergic Conjunctivitis During Conference Call And Webcast On Thursday, June 15, 2023, At 8:00 a.m. ET
Portfolio Pulse from Benzinga Newsdesk
Aldeyra Therapeutics (NASDAQ: ALDX) will announce top-line results from the Phase 3 INVIGORATE-2 Trial of reproxalap in allergic conjunctivitis during a conference call and webcast on June 15, 2023, at 8:00 a.m. ET.
June 14, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Aldeyra Therapeutics will announce Phase 3 INVIGORATE-2 Trial results for reproxalap in allergic conjunctivitis on June 15, 2023.
The announcement of top-line results from the Phase 3 INVIGORATE-2 Trial is an important milestone for Aldeyra Therapeutics. However, the short-term impact on the stock price is uncertain as it depends on the results themselves. Positive results could lead to an increase in stock price, while negative results could have the opposite effect. As the results are not yet known, the short-term impact is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100